Loading...
•
Dec 31, 2023
Zura Bio Q4 2023 Earnings Report
Zura Bio reported full year 2023 financial results and appointed Robert Lisicki as CEO.
Key Takeaways
Zura Bio reported its full year 2023 financial results, highlighting a cash balance of $99.8 million and the appointment of Robert Lisicki as CEO. The company is focused on advancing its clinical programs, including a Phase 2 trial for tibulizumab.
Appointed Robert Lisicki as CEO, effective April 8, 2024.
Plans to initiate a Phase 2 trial of tibulizumab for systemic sclerosis in 2H 2024.
Cash and cash equivalents were $99.8 million as of December 31, 2023.
Anticipates cash and cash equivalents are sufficient to fund planned operations into 2026.